Genelux Corporation (GNLX)
|Net Income (ttm)||-15.58M|
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. We expect to be in the process of obtaining Institutional Review Board approvals and negotiating clinical trial agreements to begin enrollment for our Phase 3 regi... [Read more...]
Financial PerformanceFinancial Statements
Genelux, a Phase 2 biotech developing oncolytic viral immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $30 million in an initial public offering.
Genelux has filed to go public with an IPO on the NASDAQ.